Presidio Medical, Inc., a clinical-stage, privately held medical technology company, is thrilled to announce a significant funding milestone, having raised $72,000,000 in its latest round of financing. This monumental infusion of capital marks a pivotal moment in the company’s journey as it advances its transformational neuromodulation platform, designed to treat diseases characterized by undesired neural activity. The innovative platform harnesses advanced neuromodulation technology to forge new pathways in treatment paradigms, aiming to alleviate symptoms and potentially reverse debilitating conditions that have long challenged clinicians and patients alike. With this new funding, Presidio Medical is poised to accelerate its research and development efforts, bringing cutting-edge solutions closer to market readiness. The funds will be strategically allocated to bolster clinical trials, expand the team of expert researchers and engineers, and enhance the overall infrastructure necessary to support the rigorous testing and validation processes required in the evolving field of neuromodulation. In addition, the capital enables the company to fortify its partnerships with leading healthcare institutions and regulatory bodies, ensuring adherence to the highest safety and efficacy standards. This injection of financial support underscores investor confidence in Presidio Medical’s mission and innovative approach to transforming how unwanted neural activity is managed. As the company continues to push the boundaries of science and technology in the healthcare space, stakeholders and industry observers alike are optimistic about the future prospects of this revolutionary solution and its potential to make a lasting impact on patient care worldwide.
Presidio Medical Clinches $72M Series C Round to Accelerate Transformational Neuromodulation Therapies
Recently funded · $72.0M Series cMedical Technology
Get the full Presidio Medical, Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
